Story thread · 2 reports / 1 sources
STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease
statnews.com · 15d · first report
Oak Hill Bio, a new company backed by RA Capital and other investors, will take on Ultragenyx and Ionis in developing an Angelman syndrome medicine.
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.